吃奶呻吟打开双腿做受动态图 -亚洲色偷偷色噜噜狠狠99网-日韩精品极品视频在线观看免费-来一水AV@lysav

掃碼關(guān)注公眾號           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
国产婷婷色一区二区三区在线,14表妺好紧没带套18分钟,久久国产成人午夜AV影院
Rabbit Anti-Phospho-BRCA1 (Ser1466)/PE-Cy7 Conjugated antibody (bs-20442R-PE-Cy7)
訂購熱線:400-901-9800
訂購郵箱:sales@xucheq.com
訂購QQ:  400-901-9800
技術(shù)支持:techsupport@xucheq.com
說 明 書: 100ul  
100ul/2980.00元
大包裝/詢價(jià)
產(chǎn)品編號 bs-20442R-PE-Cy7
英文名稱1 Rabbit Anti-Phospho-BRCA1 (Ser1466)/PE-Cy7 Conjugated antibody
中文名稱 PE-Cy7標(biāo)記的磷酸化乳腺癌易感基因1抗體
別    名 BRCA1 (phospho S1466); BRCA1 (phospho Ser1466); p-BRCA1 (S1466); p-BRCA1 (Ser1466); p-BRCA1 (phospho S1466); BRCA1(Phospho-Ser1423); BRCA 1; BRCA1; BRCA1/BRCA2 containing complex subunit 1; BRCA1/BRCA2-containing complex, subunit 1; BRCA1_HUMAN; BRCAI; BRAC 1; BRCA 1; BRCC 1; BRCC1; Breast Cancer 1; Breast Cancer 1 Early Onset; Breast cancer type 1 susceptibility protein; Breast and ovarian cancer susceptibility protein 1; Breast Ovarian Cancer Susceptibility; IRIS; Papillary Serous Carcinoma Of The Peritoneum; PSCP; RING finger protein 53; BROVCA1; IRIS; PNCA4; PPP1R53; Protein phosphatase 1 regulatory subunit 53; RNF53; BAP1.  
規(guī)格價(jià)格 100ul/2980元 購買        大包裝/詢價(jià)
說 明 書 100ul  
產(chǎn)品類型 磷酸化抗體 
研究領(lǐng)域 腫瘤  細(xì)胞生物  信號轉(zhuǎn)導(dǎo)  細(xì)胞凋亡  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human,  (predicted: Horse, )
產(chǎn)品應(yīng)用 Flow-Cyt=1:50-200 ICC=1:50-200 IF=1:50-200 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 208kDa
性    狀 Lyophilized or Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human Phospho-BRCA1 (Ser1466)
亞    型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹 background:
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009].

Function:
E3 ubiquitin-protein ligase that specifically mediatesthe formation of 'Lys-6'-linked polyubiquitin chains and plays acentral role in DNA repair by facilitating cellular responses toDNA damage. It is unclear whether it also mediates the formation ofother types of polyubiquitin chains. The E3 ubiquitin-proteinligase activity is required for its tumor suppressor function. TheBRCA1-BARD1 heterodimer coordinates a diverse range of cellularpathways such as DNA damage repair, ubiquitination andtranscriptional regulation to maintain genomic stability. Regulatescentrosomal microtubule nucleation. Required for normal cell cycleprogression from G2 to mitosis. Required for appropriate cell cyclearrests after ionizing irradiation in both the S-phase and the G2phase of the cell cycle. Involved in transcriptional regulation ofP21 in response to DNA damage. Required for FANCD2 targeting tosites of DNA damage. May function as a transcriptional regulator.Inhibits lipid synthesis by binding to inactive phosphorylatedACACA and preventing its dephosphorylation. Contributes tohomologous recombination repair (HRR) via its direct interactionwith PALB2, fine-tunes recombinational repair partly through itsmodulatory role in the PALB2-dependent loading of BRCA2-RAD51repair machinery at DNA breaks. Component of the BRCA1-RBBP8complex which regulates CHEK1 activation and controls cell cycleG2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination ofRBBP8.

Subunit:
Heterodimer with BARD1. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Component of the BRCA1-A complex, at least composed of the BRCA1, BARD1, UIMC1/RAP80, FAM175A/Abraxas, BRCC3/BRCC36, BRE/BRCC45 and BABAM1/NBA1. Interacts (via BRCT domains) with FAM175A/Abraxas and RBBP8. Associates with RNA polymerase II holoenzyme. Interacts with SMC1A and COBRA1/NELFB. Interacts (via BRCT domains) with phosphorylated BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with DCLRE1C/Artemis and CLSPN. Interacts with H2AFX (phosphorylated on 'Ser-140'). Interacts with CHEK1 and CHEK2. Interacts with BRCC3. Interacts (via BRCT domains) with ACACA (phosphorylated); the interaction prevents dephosphorylation of ACACA. Interacts with AURKA. Interacts with UBXN1. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with PALB2 and this interaction is essential for its function in HRR. Interacts with BRCA2 only in the presence of PALB2 which serves as the bridging protein.

Subcellular Location:
Cytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex.

Tissue Specificity:
Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.

Post-translational modifications:
Phosphorylation at Ser-308 by AURKA is required for normalcell cycle progression from G2 to mitosis. Phosphorylated inresponse to IR, UV, and various stimuli that cause checkpointactivation, probably by ATM or ATR. Phosphorylation at Ser-988 byCHEK2 regulates mitotic spindle assembly.
Autoubiquitinated, undergoes 'Lys-6'-linkedpolyubiquitination. 'Lys-6'-linked polyubiquitination does notpromote degradation.

DISEASE:
Defects in BRCA1 are a cause of susceptibility to breastcancer (BC) [MIM:114480]. A common malignancy originating frombreast epithelial tissue. Breast neoplasms can be distinguished bytheir histologic pattern. Invasive ductal carcinoma is by far themost common type. Breast cancer is etiologically and geneticallyheterogeneous. Important genetic factors have been indicated byfamilial occurrence and bilateral involvement. Mutations at morethan one locus can be involved in different families or even in thesame case. Note=Mutations in BRCA1 are thought to be responsiblefor 45% of inherited breast cancer. Moreover, BRCA1 carriers have a4-fold increased risk of colon cancer, whereas male carriers face a3-fold increased risk of prostate cancer. Cells lacking BRCA1 showdefects in DNA repair by homologous recombination.
Defects in BRCA1 are a cause of susceptibility tofamilial breast-ovarian cancer type 1 (BROVCA1) [MIM:604370]. Acondition associated with familial predisposition to cancer of thebreast and ovaries. Characteristic features in affected familiesare an early age of onset of breast cancer (often before age 50),increased chance of bilateral cancers (cancer that develop in bothbreasts, or both ovaries, independently), frequent occurrence ofbreast cancer among men, increased incidence of tumors of otherspecific organs, such as the prostate. Note=Mutations in BRCA1 arethought to be responsible for more than 80% of inheritedbreast-ovarian cancer.
Defects in BRCA1 are a cause of susceptibility to ovariancancer (OC) [MIM:167000]. The term ovarian cancer definesmalignancies originating from ovarian tissue. Although manyhistologic types of ovarian tumors have been described, epithelialovarian carcinoma is the most common form. Ovarian cancers areoften asymptomatic and the recognized signs and symptoms, even oflate-stage disease, are vague. Consequently, most patients arediagnosed with advanced disease.
Defects in BRCA1 are a cause of susceptibility topancreatic cancer type 4 (PNCA4)

Similarity:
Contains 2 BRCT domains.
Contains 1 RING-type zinc finger.

Database links:

Entrez Gene: 672 Human

Omim: 113705 Human

SwissProt: P38398 Human

Unigene: 194143 Human



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
版權(quán)所有 2004-2026 www.xucheq.com 北京博奧森生物技術(shù)有限公司
通過國際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號
我把五十老女人弄高潮了| 97精品一区二区视频在线观看| 最近免费中文字幕中文高清百度| 国产无遮挡又黄又爽在线观看| 国产精品99无码一区二区| 少妇特黄A片一区二区三区蜜桃| 国产zzjjzzjj视频全免费| 国内老熟妇对白HDXXXX| 一本狠狠色丁香婷婷综合久久| 人妻体体内射精一区二区| 大乳丰满人妻中文字幕日本| 18禁免费无码无遮挡不卡网站 | 久久精品国产亚洲AV高清热| 无码视频一区二区三区| 精品香蕉一区二区三区| japanesehd熟女熟妇| 双胞胎(H)互攻| 最近韩国日本免费高清观看| 欧美性受XXXX白人性爽| 欧美人与性动交α欧美精品| 色噜噜狠狠色综合日日| 在办公室伦流澡到高潮H| 色翁荡熄又大又硬又粗又| 日韩人妻无码免费视频一区二区三区| 国产白嫩护士被弄高潮| 日本无码小泬粉嫩精品图| 久久人人添人人爽添人人片牛牛 | 国产午夜福利视频在线观看| 全黄H全肉禁乱公| AV无码专区| 欧美大片VA欧美在线播放| 免费无遮挡无码永久在线观看视频| 医院人妻闷声隔着帘子被中出 | 少妇愉情理伦片高潮日本| 丝袜老师办公室里做好紧好爽| 嗯灬啊灬把腿张开灬A片小说| 欧美成A人片在线观看久| 男女无遮挡XX00动态图120秒| 久久久亚洲精品无码| 亚洲尺码与欧洲尺码区别入口跳转| 风韵多水的老熟妇|